Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10610527 | 0.93 | SMN1; SMN2 (0.43) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL8056909 | 0.84 | LMNA (0.44) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL14950071 | 0.84 | LMNA (0.41) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL20658869 | 0.80 | LMNA (0.45) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL866289 | 0.79 | LMNA (0.53) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL20658878 | 0.78 | LMNA (0.42) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL20658873 | 0.78 | LMNA (0.46) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL27731125 | 0.78 | LMNA (0.57) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL8736742 | 0.77 | LMNA (0.44) | LMNAMAPTKDM4EMEN1CYP1A2 | |
| SCHEMBL4531830 | 0.77 | LMNA (0.49) | LMNAMAPTKDM4EMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084499-B2 | Modified clay mineral | AJINOMOTO CO., INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090098169-A1 | MODIFIED CLAY MINERAL | AJINOMOTO CO., INC (JP) | 2009-04-16 | — | — | US | disclosed |
| US-4863952-A | Method of promoting percutaneous drug absorption with 2-pyrrolidin-2-one 5-carboxylic acids and esters thereof | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098169-A1 | MODIFIED CLAY MINERAL | CUTA, ARG1, AS3MT | LMNA 323/4885MAPT 3302/4885KDM4E 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.